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Trans-vaccenic acid (TVA; trans-11-18: 1) is a natural trans fatty acid, found in foods derived from ruminant animals, in particular dairy products, and is formed through biohydrogenation of unsaturated fatty acids by ruminal bacteria (Sommerfeld, 1983; Slattery et al. 2001) . TVA is believed to have potential positive effects on health due to its partial metabolic conversion to rumenic acid, the well-known cis-9, trans-11-conjugated linoleic acid (c9, t11-CLA) (Lock et al. 2004) . Since TVA is the precursor of CLA, it is important to understand whether its intestinal absorption and metabolism can be modulated by other nutrients (Lin et al. 2004) , thus affecting the bio-potency of CLA.
The enzyme responsible for the conversion of TVA to c9, t11-CLA is stearoyl-CoA desaturase (SCD). SCD classically converts stearoyl-CoA into oleoyl-CoA. This enzyme has been studied for a long time, due to this crucial role in regulating the unsaturated:saturated ratio, which in turn influences many cellular functions including the fluidity of the cell membranes (Kim & Ntambi, 1999) . SCD is strongly modulated by nutrients, drugs, environmental factors (for a review, see Ntambi & Miyazaki, 2004) . To our knowledge, from all substances known to act on the D-9 desaturation process, only sterculic acid (Lock et al. 2004 ) has been studied for its effects on the conversion of TVA to c9, t11-CLA. Nutrients, in particular fatty acids, regulate SCD both at the transcription and enzyme activity levels. The half-life of the SCD mRNA can be shortened by the PUFA arachidonic acid (Sessler et al. 1996) . The amount of SCD mRNA can also be regulated by several transcription factors, including sterol regulatory-element binding protein-1c and PPARa. So far, SCD is the only gene identified to be under the control of both factors (Nakamura & Nara, 2002) , which is unusual since SREBP-1c regulates lipid synthesis and PPARa lipid oxidation.
The present study investigated the effect of EPA and 3,10-dithia stearic acid (DSA) on SCD mRNA levels and intestinal TVA metabolism in two well characterised polarised cell culture systems, Caco-2 and T84 cells, models of the lipid metabolism in human intestinal epithelial cells (Black et al. 2002b) . EPA, a natural n-3 PUFA, is a well-known inhibitor of SCD (Ntambi, 1999) . DSA is a fatty acid analogue with sulfur atoms substituting methylene groups in the carbon chain at the third and tenth positions. DSA has been used as SCD inhibitor in 7800 CI Morris hepatoma cells and rat hepatocytes (Hovik et al. 1997) . To date, little is known of the mechanism whereby fatty acid inhibitors of SCD modulate TVA metabolism in the gut, which is relevant within the context of TVA and CLA bioavailability, as well as intestinal lipid metabolism. Therefore, the objective of the present study was to understand the interactions between acute (3 h) and acute-on-chronic (3 h following 7 d fatty acid pre-treatment) effects of the natural fatty acid EPA v. the sulfur-modified fatty acid DSA on SCD mRNA abundance and TVA metabolism.
Materials and methods

Cell culture
Several experiments have investigated TVA metabolism in hepatic (Gruffat et al. 2005) and mammary (Loor et al. 2002 (Loor et al. , 2003 Lin et al. 2004 ) cells but little is know of its effect in intestinal cells. The intestine is the first organ to be exposed to and metabolise fatty acids; there, fatty acids are metabolised and incorporated into chylomicrons. It plays a key role in determining the exposure of other organs to dietary fatty acids (Black et al. 2002a,b) . Therefore, the epithelial cell lines Caco-2 and T84 were chosen as in vitro models of intestinal epithelium, to investigate the effect of EPA and DSA on intestinal TVA metabolism.
The two cell lines were obtained from the European Collection of Animal Cell Cultures (Salisbury, Wiltshire, UK). Caco-2 and T84 cells were grown in a 1:1 mixture of Ham's F12 and Dulbecco's modified Eagle's medium (Sigma, Poole, Dorset, UK), which was supplemented with L-glutamine (2 mM; Sigma), penicillin (100 U/ml; Sigma), streptomycin (100 mg/ml; Sigma) and 10 % fetal calf serum (GibcoBRL, Paisley, UK). They were incubated in flasks at 378C in a humidified atmosphere of 5 % CO 2 and split using a trypsin -EDTA solution (Sigma). Cells were seeded at a density of 3 £ 10 5 cells per 24 mm polycarbonate transwell (growth area 4·7 cm 2 ; pore size 0·4 mm; Costar, High Wycombe, Bucks, UK) and grown for 14 d. Apical and basolateral media were changed once per d during the course of cell growth and development. Cell passages used were between 51 and 52 for Caco-2 cells and between 48 and 49 for T84 cells.
Experimental design
The present study was designed to determine the acute (3 h) and acute-on-chronic (3 h following 7 d fatty acid pre-treatment) effects of EPA and DSA on TVA metabolism. For clarity, treatment refers to acute effects and supplementation refers to chronic effects of fatty acids.
The acute effects of EPA and DSA (kindly supplied by Professor Spydevold, Oslo, Norway) were determined in Caco-2 and T84 cells that had been grown for 14 d in standard conditions. For the acute treatment, cells were then incubated for 30 min with 1 mM-taurocholate and 0·3 mM-EPA or DSA, and finally for 3 h with 1 mM-taurocholate, 0·3 mM-TVA, 0·3 mM-EPA or -DSA before harvesting. These fatty acid concentrations were not toxic and were chosen as possibly physiological on the basis of TVA and EPA dietary intake (Wolff, 1995; Astorg et al., 2004) . Taurocholate was used in order to mimic intestinal lumen fatty acids emulsion (Field et al. 2002) .
To investigate the acute-on-chronic effect of fatty acid supplementation on cell TVA metabolism, the cells received, after 7 d of culture in standard conditions, chronic fatty acid supplementation (1 mM-taurocholate and 0·03 mM-EPA or -DSA) for 7d, followed by 3 h acute treatment (1 mMtaurocholate, 0·3 mM-TVA, 0·3 mM-EPA or -DSA) before harvesting.
EPA and DSA were stored in ethanol at 2 208C. Sodium taurocholate was added (1 mM) in order to make the fatty acids soluble in the media. The fatty acid supplements were added to the apical compartment of the transwells; the basolateral compartment did not receive fatty acid supplementation. This was done to mimic the intestinal epithelium where only the apical surface of enterocytes is exposed to dietary fats.
Cell viability
The effect of 0·3 or 0·03 mM-EPA, -DSA or -TVA on Caco-2 or T84 cells proliferation was investigated using the Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay and protocol (Promega, Madison, WI, USA). Briefly, cells receiving each fatty acid treatment were seeded in ninety-six-well microtitre plates (Falcon; Becton-Dickinson Labware, Lincoln Park, NJ, USA) at a density of 10 5 cells/well and grown for 24 h. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-phenazine methosulfate solution (20 ml) was added to each well and cells were incubated for 4 h at 378C before absorbance reading at 490 nm. Results of the MTS proliferation assay of Caco-2 cells and T84 supplemented with 0·03 or 0·3 mM-TVA, -EPA or -DSA are presented in Table 1 . ANOVA demonstrated that the treatments used in these experiments did not affect the proliferation of either cell line.
The transepithelial electrical resistance (TER) of Caco-2 and T84 cells growing in the inserts was measured with the Endohm apparatus (World Precision Instruments, Sarasota, FL, USA) at 24 h intervals. TER increased progressively during approximately 8-10 d until confluence, when cells formed high-resistance monolayers with stable TER values of 340 (SEM 93) V/cm 2 (n 48) for T84 cells and 179 (SEM 34) V/cm 2 (n 48) for Caco-2 cells. In Caco-2 cells, the supplementations with either EPA or DSA had no significant effect on TER values compared with control cells. TER values of T84 cells supplemented with 0·03 mM-EPA or -DSA are presented in Fig. 1 . In T84 cells, DSA was associated with a marked decrease of TER compared with cells supplemented with EPA or control cells.
mRNA abundance
Total RNA was extracted from cells using TriZOL reagent and protocol from Invitrogen (Paisley, UK). The mRNA levels of SCD, PPARa and SREBP-1c was analysed using Taq-Man quantitative real-time PCR.
RNA (2 mg) was treated with RNase-free DNase to remove contaminating genomic DNA (DNAase I Amplification Grade; Invitrogen). After inactivating the DNase by the addition of 1·5 ml EDTA (25 mM) and heating at 658C for 10 min, total RNA was reverse-transcribed for 1 h at 378C followed by 10 min at 708C in a 25 ml reaction mixture containing 5 ml RT buffer (50 mM-Tris-HCl, 75 mM-KCl, 3 mM-MgCl 2 , 10 mM-dithiothreitol), 500 ng random primers, 0·4 mMdNTPs, and 300 units Moloney murine leukaemia virus RT (Promega). Reactions in which Moloney murine leukaemia virus RT was omitted served as negative controls. As a standard, five samples were reverse-transcript; these five samples were pooled after first-strand cDNA synthesis. This standard was serially diluted 1:2 in DNase -free water to generate a standard curve for the PCR analysis. Samples were diluted in diethyl pyrocarbonate-water (Sigma) in order to obtain a final concentration of 20 ng/ml. SCD and PPARa mRNA were quantified using Assayon-Demand gene expression assays (Applied Biosystems, Warrington, Cheshire, UK). Oligonucleotide primers and Taq-Man probe sequences for SREBP-1c were as follows: forward-5 0 CCATGGATTGCACTTTCGAA3 0 , reverse-5 0 CCA-GCATAGGGTGGGTCAAA3 0 , and probe-5 0 TATCAACAACC-AAGACAGTGACTTCCCTGGC3 0 (as described in Sewter et al. 2002) . The Taq-Man probe was labelled at the 5 0 end with the reporter dye 6-carboxy-fluorescein and at the 3 0 end with the quencher 6-carboxy-tetramethyl-rhodamine. Oligonucleotide primers and Taq-Man probes for the glyceraldehyde-3-phosphate dehydrogenase, used as internal control, were purchased from Applied Biosystems. PCR was carried out in duplicate for each sample on an ABI 7700-sequence detection system (Applied Biosystems).
Each 25 ml reaction mixture contained 2 ml first-strand cDNA, 1X PCR master mix, 1·25 ml Assay-on-Demand for SCD and PPARa or SREBP-1c forward and reverse (500 nmol/l) and 250 nmol SREBP-1c Taq-Man probe. All reactions were carried out using the following cycling parameters: 508C for 2 min, 958C for 10 min, followed by forty cycles of 958C for 15 s and 608C for 1 min.
After PCR, standard curves were constructed from the standard reactions for each target gene and internal control by plotting Ct values, i.e. the cycle number at which the fluorescence signal exceeds background v. log cDNA input (ng). The Ct readings for each of the unknown samples were then used to calculate the amount of either target or internal control relative to the standard. For each sample, results were normalised by dividing the amount of target by the amount of internal control. Repeatability of the PCR was examined by measuring the Ct readings of three samples.
Fatty acid analysis
Cells were washed twice with cold PBS, scraped into 15 ml tubes, pelleted at 800 g for 5 min before being stored at 2 808C. Total cellular lipids were extracted following the chloroform-methanol (1:1) procedure of Bligh & Dyer (1959) . As acid methylation induces isomerisation of CLA in a time-and temperature-correlated manner, the baseacid methylation parameters were optimised as previously described (Park et al. 2001) to minimise isomerisation of cis-trans bonds, artefact formation and to ensure that all fatty acids were methylated. The lipid extracts were dried under N 2 , converted to fatty acid methyl esters using 1 ml 0·1 M-KOH -methanol at 708C for 1 h followed by 0·4 ml 1·2 M-HCl -methanol at 708C for 15 min and extracted with hexane. The fatty acid methyl esters were separated by GC, conducted with a Thermo Finnigan Trace GC (Interscience, Milan, Italy) fitted with a flame ionisation detector and Chromquest 3.0 integrator (Thermo Finnigan, San Jose, CA, USA). A Restek RT-2560 (Bellefonte, PA, USA) fused silica capillary column (100 m £ 0·25 mm internal diameter, 0·2 mm film thickness) was used. The oven temperature was increased at 258C/min from 80 to 1758C, and held for 25 min. The temperature was then increased at 108C/min to 2058C and held for 4 min. Finally, it was increased at 108C/min to 2258C and held for 20 min. H 2 was used as the carrier gas. The fatty acid methyl esters were identified 
Statistical analysis
Fatty acid data were analysed by the general linear model procedure of SAS (SAS Institute Inc., Cary, NC, USA). ANOVA was used to identify the effect of treatment and differences between treatment means were identified using the probability of difference option of the least significant means command. Two-way ANOVA was used to test the effect of fatty acid treatment (control, EPA and DSA), type of treatment (acute and acute-on-chronic) and their interaction term. Treatment effects and differences between means were considered significant when P,0·05.
Results
Cellular fatty acid composition
The fatty acid composition of Caco-2 cells (Table 2) shows the most important changes occurred following the acute-onchronic rather than the acute fatty acid treatment. Acute-onchronic EPA treatment significantly (P, 0·05) reduced oleic acid levels, a product of SCD activity, but acute-on-chronic DSA treatment did not. Oleic acid was reduced following acute EPA and DSA treatments, but these changes were not significant. Both acute and acute-on-chronic EPA treatments significantly reduced TVA levels (P, 0·01) and c9, t11-CLA levels (P, 0·01). Acute and acute-on-chronic DSA treatments significantly reduced c9, t11-CLA only (P,0·01). EPA was incorporated in cellular lipids and was elongated to 22: 5n-3, but was not desaturated into DHA (22: 6n-3), following both acute and acute-on-chronic fatty acid treatments. Similar fatty acid profiles were observed in T84 cells (results not shown).
Stearoyl-CoA desaturase desaturation index
In both cell lines, the SCD desaturation index was defined as the oleic acid:oleic plus stearic acids ratio. The SCD desaturation index was not affected by any acute treatment, but the acute-on-chronic treatment with EPA, and to a lesser extent with DSA, reduced the desaturation levels of stearic acid ( Fig. 2(A) ). Supplementation of the nutritive media with EPA also reduced the desaturation of TVA but the acute treatment did not (Fig. 2(B) ). Both acute and acute-on-chronic exposures with DSA reduced SCD desaturation indices. The effects were similar on both cell lines but, in T84, the desaturation of TVA was lower. SCD desaturation of TVA is quickly inhibited by DSA during the acute treatment, even after 1 h (results not shown), which suggests that DSA acts directly on the enzyme. To obtain inhibition of SCD by EPA, a longer duration was required, which suggests an effect limited to the transcription level. In both cell lines, the two-way ANOVA analysis on desaturation indices indicated that fatty acid treatment, type of treatment and their interaction were highly significant (P, 0·01); this illustrates 2·50  0·57  2·28  0·16  2·15  0·51  1·97  0·20  2·89  1·37  1·72  0·40  12 : 0  3·10  0·59  2·65  0·42  2·62  0·73  2·49  0·16  2·79  1·21  2·44  0·67  14 : 0  18·63  2·76  16·91  1·45  17·40  3·22  16·75  0·34  16·79  1·28  14·31  3·43  16 : 0  171·67  25·28  139·87  12·80  141·40  17·06  139·08  5·79  138·34  4·16  111·96  13·86  16 : 1t9 , 8·38  1·21  6·71  0·43  6·55  0·65  6·41  0·23  5·56  0·37  6·41  0·84  20 : 4n-6  34·80  5·83  21·53  9·68  28·11  2·87  26·01  0·63  24·21  2·18  25·85  2·88  20 : 5n-3  4·76  0·58  90·65**  9·53  4·22  0·25  3·77  0·30  117·79**  11·6  3·61  0·23  22 : 5n-3  13·46  1·76  21·71*  2·09  10·26  1·10  10·21  0·49  76·50**  6·38  10·22  1·68  22 : 6n-3  14·04  2·29  11·32  1·17  11·14  1·11  10·58  0·10  8·97  0·78  10·46  1·24 Mean value was significantly different from that of the control: * P,0·05; ** P,0·01.
that acute-on-chronic treatment had more profound effects on fatty acid composition compared with acute treatment alone.
Stearoyl-CoA desaturase mRNA abundance
In both cell lines, the acute EPA and DSA treatments did not alter SCD mRNA levels (( Fig. 3(A) and Fig. 3(B) ). In contrast acute-on-chronic EPA supplementation induced a marked decrease in SCD mRNA levels in Caco-2 cells (1·27 (SD 0·23) v. 0·74 (SD 0·05); P, 0·05). But acute-on-chronic DSA supplementation did not. This effect of EPA may explain the effect observed on the desaturation index following EPA acute-on-chronic condition as presented in Fig. 2 . EPA supplementation also reduced SCD mRNA levels in T84 cells. In contrast, DSA supplementation significantly increased SCD mRNA levels in T84 cells.
mRNA levels of stearoyl-CoA desaturase transcription factors: sterol regulatory-element binding protein-1c and peroxisome proliferator-activated receptor a
The transcription of SCD is under the control of two transcription factors, SREBP-1c and PPARa (Nakamura & Nara, 2002) . We investigated whether the mRNA levels of SREBP1c or PPARa was altered by acute or acute-on-chronic administrations of EPA or DSA. In our experiments, the transcription of SREBP-1c was reduced by the acute-on-chronic fatty acid interventions ( Fig. 3(C) ), but the decrease by DSA was lower than that observed with EPA. No differences in mRNA levels of PPARa (Fig. 3(D) ) were observed for any exposure. Neither SREBP-1c nor PPARa mRNA levels were altered by acute treatments with EPA or DSA (results not shown).
Discussion
TVA is the precursor of c9, t11-CLA, a fatty acid that has been associated with potential anti-carcinogenic, anti-diabetic, anti-inflammatory and cardioprotective effects (Belury, 2002; Roche et al. 2002; Toomey et al. 2003; Field & Schley, 2004; McLeod et al. 2004; O'Shea et al. 2004; Wang & Jones, 2004) . We addressed the hypothesis that intestinal TVA absorption and biotransformation into CLA can be modulated by other nutrients or xenobiotics. Therefore, the present study aimed at investigating whether TVA is metabolised in differentiated intestinal cells and determined whether intestinal TVA metabolism can be modified by PUFA. The enzyme SCD (also referred to as D9-desaturase; EC 1·14·99·5) catalyses the insertion of a cis double bond in ninth position in the carbon chain of saturated and unsaturated fatty acids, including TVA. It has been suggested that several nutrients (PUFA and fructose), drugs (thia fatty acids and sterculic acid) and hormones (insulin and leptin) modulate SCD expression and activity, as reviewed in Ntambi & Miyazaki (2004) . Moreover mouse in vivo studies (Loor et al. 2002, 2003; Lin et al. 2004 ) demonstrated that TVA metabolism can be modulated by diet composition. The present study focused on the effect of EPA on SCD mRNA levels and TVA metabolism because preliminary work in Caco-2 cells demonstrated that EPA was the most effective PUFA to reduce SCD desaturation indices in Caco-2 cells (B Renaville, YJ Schneider and Y Larondelle, unpublished results) . In addition, the metabolic effects of DSA, a known pharmacological inhibitor of SCD (Hovik et al. 1997) , were investigated in order to act as a comparison to the natural fatty acid EPA.
In vivo studies demonstrated that desaturation indices do not always reflect enzyme activity (Archibeque et al. 2005) , in part because ingestion of SCD substrates and products may vary between diets. Nevertheless, in our in vitro model, SCD substrate fatty acid supply was constant, therefore desaturation products could not be derived from other fatty acid sources. Hence we propose that the SCD desaturation index could be ascribed to different SCD activity, albeit a surrogate marker for SCD activity. Overall the present results showed that acute EPA and DSA treatments were insufficient to cause consistent changes in SCD mRNA levels, SCD activity on oleic acid and alter fatty acid composition, in comparison with the acute-on-chronic effect of fatty acid interventions. This is probably related to insufficient time for the fatty acids to induce important effects, as previously observed (Black et al. 2002b) . Neither acute EPA nor DSA reduced oleic acid levels and oleic desaturation indices. Acute DSA treatment significantly reduced CLA levels and desaturation indices. Whilst acute EPA treatment reduced CLA concentration, it had no effect on the SCD desaturation index, an effect which may be ascribed to altered TVA absorption. Acute-on-chronic EPA reduced TVA, oleic and CLA concentrations, which were associated with lower SCD desaturation indices and lower SCD and SREBP-1c mRNA levels. This discrepancy between acute and acute-on-chronic EPA effects probably reflects the cumulative effect of fatty acid exposure over time (Black et al. 2002b) . The chronic effect of EPA on SREBP-1c mRNA levels in Caco-2 cells agrees with previous work (Field et al. 2002) . Since the transcription factor SREBP-1c regulates SCD gene transcription, we suggest that the effect of EPA on SCD mRNA levels was mediated by SREBP-1c. We propose that lowered levels of SREBP-1c would decrease SCD gene transcription and expression, which would in turn decrease the SCD activity on TVA.
The effects of DSA were different from those of EPA. Furthermore, DSA had different effects in the two cell lines studied. In Caco-2 cells, acute treatment and acute-on-chronic supplementation with DSA significantly reduced SCD desaturation indices and CLA concentrations, but did not alter SCD mRNA levels, suggesting that DSA directly acts on SCD at the protein level, reducing the desaturation of TVA by competition, as suggested by Hovik et al. (1997) . In T84 cells, again both types of treatment significantly reduced SCD desaturation indices. However, the acute-on-chronic DSA condition increased SCD mRNA levels in T84 cells. The differential effect of DSA on transcription and translation could be related to time-related differences in the expression and activity of SCD, between the two cell lines used. Otherwise the thia group in third position of the chain is known to activate SCD transcription (Madsen et al. 1997 ), whereas the tenth sulfur substitute to methylene is known to inhibit the activity of SCD (Hovik et al. 1997) , which could be related to the opposite effects of DSA on activity and transcription of SCD in T84 cells. Acute-on-chronic DSA treatment also reduced SREBP-1c mRNA levels but this was not associated with lower SCD mRNA levels. This implies that lower SREBP-1c mRNA levels were insufficient to alter or were not correlated with transcriptional activity. PPARa is a key transcription factor that regulates fatty acid oxidation, especially in the liver. Given the regulatory relationship between SCD and PPARa, we determined whether alterations in SCD mRNA levels could be explained by differential intestinal PPARa mRNA levels. In the present study, neither EPA nor DSA had any effect on the PPARa mRNA levels. Nutritionists may recommend increased consumption of c9, t11-CLA and long-chain PUFA. The production costs of pure c9, t11-CLA supplements are prohibitive, therefore naturally enriched CLA meat and dairy products, containing c9, t11-CLA and its precursor TVA, could become a good alternative to fatty acid supplementation (Corl et al. 2003) . The research presented here in relation to the intestinal desaturation of TVA is highly relevant within the context of any potential health benefits of food sources of TVA and CLA. The results suggest that EPA could decrease the positive effects of TVA, by inhibiting its intestinal desaturation, illustrating once again the potential interactions between nutrients at the intestinal level.
